This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Geron: Super Important Imetelstat Data Coming Thursday

Geron has not disclosed the nature of these imetelstat responses, which is why the reveal of the ASH abstract on Thursday is such a big deal.

Investors want to see partial remissions (PRs) in the imetelsat abstract. Complete remissions (CRs) would be amazing but perhaps less likely because the drug's mechanism of action isn't well suited to reducing spleen size.

So, look for PRs in the ASH abstract. The more PRs, the better, and the more likely Geron's stock rally will continue. Just note that at Monday's close of $4.01, Geron is already worth more than $500 million, raising the risk of a stock sell off regardless of how good the imetelstat data look. Compounded by the high likelihood Geron raises money to fund future imetelstat studies.

But Geron shares will almost certainly fall -- and far -- if imetelstat only manages to produce clinical improvements (CIs) in the Tefferi study. This outcome won't differentiate imetelstat enough from Jakafi to matter much.

For those interested in how CIs, PRs and CRs are measured in myelofibrosis studies, here's an outline, courtesy of Geron:

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GERN $4.14 4.28%
INCY $105.51 3.79%
AAPL $127.60 2.28%
FB $83.09 2.87%
GOOG $535.38 2.16%


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs